Table 5.
Molecular differences between CRC tumours found in FCCTX vs. LS patients [15].
| __ |
Tumours from MMR Mutation Negative HNPCC
Patients (FCCTX) |
% | Tumours from MMR Mutation Positive HNPCC Patients (LS) | % | P-value |
|---|---|---|---|---|---|
| MSI | 2 out of 24 | 8% | 31 out of 31 | 100% | Not given |
| Aberrant beta-catenin (Nuclear, cytosolic) | 7 out of 18 | 39% | 25 out of 31 | 81% | 0.005 |
| Membranous beta-catenin | 11 out of 18 | 61% | 6 out of 31 | 19% | 0.005 |
| CTNNB1 mutation | 0 out of 24 | 0% | 9 out of 31 | 29% | 0.007 |
| Loss of APC expression | 6 out of 7 (tumours with aberrant beta-catenin) |
86% (tumours with aberrant beta-catenin) |
Not given | Not given | - |
| Loss of APC locus | 4 out of 7 (tumours with aberrant beta-catenin) |
57% (tumours with aberrant beta-catenin) |
Not given | Not given | - |
| p53 protein stabilisation | 8 out of 18 | 44% | 4 out of 31 | 13% | 0.041 |
| p53 mutation | 5 out of 8 (tumours with p53 stabilisation) |
63% | 4 out of 4 (tumours with p53 stabilisation) |
100% | Not significant |
| CIN+ | 7 out of 16 | 44% | Not given | Not given | - |
1 P-value= 0.04 is given in textbox, while p-value=0.02 is given in text.